SOURCE-LINKED STUDY SUMMARY
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
Abstract summarizedQuality not appraised
- What was studied
- A phase 2 trial tested the SARM enobosarm for lean mass, physical function, and safety in patients with cancer-related weight loss.
- Who / model studied
- The safety population included 159 non-obese adults with cancer and at least 2% weight loss; 100 had protocol-window measurements for efficacy analysis.
- Studied dose & schedule
- Participants received oral enobosarm 1 mg, enobosarm 3 mg, or placebo once daily for up to 113 days.
- What the study found
- Lean mass increased from baseline by a median 1.5 kg with 1 mg and 1.0 kg with 3 mg; placebo changed 0.02 kg. Common serious events reflected cancer complications and were not considered drug-related.
- Limitations & context
- These were within-group changes, not reported between-group treatment effects. Only 100 participants entered the evaluable efficacy analysis, and DXA lean mass does not directly measure muscle hypertrophy.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s1470-2045(13)70055-x